Drug Companies Call for Interchangeability Information in Purple Book

Several leading drugmakers — including Janssen, Novo Nordisk and Genentech — urged the FDA to include new information on interchangeable products in the agency’s Purple Book, which lists biological products including biosimilars and interchangeables licensed by the agency.
Source: Drug Industry Daily